• US therapeutic: $429M (-9% QoQ*, +8% YoY) • US cosmetic: $305M (+1 QoQ*, +43% YoY) -- US total: $734M (58% therapeutic; 42% cosmetic) was 73% of worldwide total
• Ex-US therapeutic: $103M (+8% QoQ*, +15% YoY) • Ex-US cosmetic: $172M (-9% QoQ*, +51% YoY) -- Ex-US total: $275M (37% therapeutic; 63% cosmetic) was 27% of worldwide total
*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.